Product nameAnti-p73 (phospho Y99) antibody [EPR21751]
See all p73 primary antibodies
DescriptionRabbit monoclonal [EPR21751] to p73 (phospho Y99)
Tested applicationsSuitable for: Dot blot, WB, IPmore details
Species reactivityReacts with: Human
Synthetic peptide within Human p73 aa 50-150 (phospho Y99). The exact sequence is proprietary.
Database link: O15350
- WB: HT-1376 treated with 1 mM pervanadate for 30 minutes, whole cell lysate. IP: HT-1376 treated with 1 mM pervanadate for 30 minutes, whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab218625 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 80 kDa (predicted molecular weight: 69 kDa).|
FunctionParticipates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.
Tissue specificityExpressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue.
Sequence similaritiesBelongs to the p53 family.
Contains 1 SAM (sterile alpha motif) domain.
DomainPossesses an acidic transactivation domain, a central DNA binding domain and a C-terminal oligomerization domain that binds to the ABL tyrosine kinase SH3 domain.
The WW-binding motif mediates interaction with WWOX.
modificationsIsoform alpha (but not isoform beta) is sumoylated on Lys-627, which potentiates proteasomal degradation but does not affect transcriptional activity.
Higher levels of phosphorylation seen in the brain from patients with Huntington disease.
Ubiquitinated; leading to its degradation by the proteasome.
Cellular localizationNucleus. Accumulates in the nucleus in response to DNA damage.
- Information by UniProt
- p53 like transcription factor antibody
- p53 related protein antibody
- p53-like transcription factor antibody
All lanes : Anti-p73 (phospho Y99) antibody [EPR21751] (ab218625) at 1/1000 dilution
Lane 1 : Untreated HT-1376 (human urinary bladder carcinoma cell line) whole cell lysate
Lane 2 : HT-1376 treated with 1 mM pervanadate for 30 minutes, whole cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 69 kDa
Observed band size: 80 kDa why is the actual band size different from the predicted?
Exposure time: 15 seconds
Blocking/Dilution buffer: 5% NFDM/TBST.
The molecular mass observed is consistent with the literature (PMID:11466610).
p73 (phospho Y99) was immunoprecipitated from 0.35 mg of HT-1376 (human urinary bladder carcinoma cell line) treated with 1mM Pervanadate for 30 min whole cell lysate with ab218625 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab218625 at 1/2000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1/10000 dilution.
Lane 1: HT-1376 treated with 1mM Pervanadate for 30 min whole cell lysate 10 μg (input).
Lane 2: ab218625 IP in HT-1376 treated with 1mM Pervanadate for 30 min whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab218625 in HT-1376 treated with 1mM Pervanadate for 30 min whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 seconds.
Dot blot analysis of p73 (phospho Y99) with ab218625 at 1/1000 dilution.
Lane 1: p73 (phospho Y99) peptide.
Lane 2: p73 non-phospho peptide.
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution was used as secondary antibody.
Blocking/Dilution buffer: 5% NFDM/TBST.
ab218625 has not yet been referenced specifically in any publications.